Daré Bioscience, Inc.
DARE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $2 | -$21 | $25 | -$64 |
| % Growth | 110.7% | -183.3% | 140% | – |
| Cost of Goods Sold | $613 | $0 | $2,297 | $14,223 |
| Gross Profit | -$611 | -$21 | -$2,272 | -$14,286 |
| % Margin | -26,993.9% | 100% | -8,935.2% | 22,446% |
| R&D Expenses | $693 | $1,429 | $2,297 | $3,311 |
| G&A Expenses | $0 | $2,378 | $1,943 | $1,781 |
| SG&A Expenses | $2,368 | $2,378 | $2,309 | $1,996 |
| Sales & Mktg Exp. | $0 | $0 | $366 | $215 |
| Other Operating Expenses | $0 | $0 | -$2,297 | -$14,205 |
| Operating Expenses | $3,062 | $3,807 | $2,309 | -$8,898 |
| Operating Income | -$3,672 | -$3,828 | -$4,581 | -$5,388 |
| % Margin | -162,340.8% | 18,079.5% | -18,016.7% | 8,465.8% |
| Other Income/Exp. Net | $109 | -$189 | $203 | -$118 |
| Pre-Tax Income | -$3,563 | -$4,016 | -$4,378 | -$5,506 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,563 | -$4,016 | -$4,378 | -$5,506 |
| % Margin | -157,505.1% | 18,970.7% | -17,219.1% | 8,651.5% |
| EPS | -0.279 | -0.45 | -0.5 | -0.65 |
| % Growth | 37.9% | 10% | 23.1% | – |
| EPS Diluted | -0.279 | -0.45 | -0.5 | -0.65 |
| Weighted Avg Shares Out | 12,755 | 8,871 | 8,759 | 8,497 |
| Weighted Avg Shares Out Dil | 12,755 | 8,871 | 8,759 | 8,497 |
| Supplemental Information | – | – | – | – |
| Interest Income | $319 | $70 | $0 | $0 |
| Interest Expense | $213 | $269 | $0 | $0 |
| Depreciation & Amortization | $613 | $460 | $158 | $6 |
| EBITDA | -$2,737 | -$3,368 | -$4,423 | -$5,382 |
| % Margin | -120,987.2% | 15,906.5% | -17,394.9% | 8,455.7% |